Literature DB >> 33320513

Peripheral Neuropathy: Evaluation and Differential Diagnosis.

Gregory Castelli1, Krishna M Desai2, Rebecca E Cantone3.   

Abstract

Peripheral neuropathy, a common neurologic problem encountered by family physicians, can be classified clinically by the anatomic pattern of presenting symptoms and, if indicated, by results of electrodiagnostic studies for axonal and demyelinating disease. The prevalence of peripheral neuropathy in the general population ranges from 1% to 7%, with higher rates among those older than 50 years. Common identifiable causes include diabetes mellitus, nerve compression or injury, alcohol use, toxin exposure, hereditary diseases, and nutritional deficiencies. Peripheral neuropathy is idiopathic in 25% to 46% of cases. Diagnosis requires a comprehensive history, physical examination, and judicious laboratory testing. Early peripheral neuropathy may present as sensory alterations that are often progressive, including sensory loss, numbness, pain, or burning sensations in a "stocking and glove" distribution of the extremities. Later stages may involve proximal numbness, distal weakness, or atrophy. Physical examination should include a comprehensive neurologic and musculoskeletal evaluation. If the peripheral nervous system is identified as the likely source of the patient's symptoms, evaluation for potential underlying etiologies should initially focus on treatable causes. Initial laboratory evaluation includes a complete blood count; a comprehensive metabolic profile; fasting blood glucose, vitamin B12, and thyroid-stimulating hormone levels; and serum protein electrophoresis with immunofixation. If the initial evaluation is inconclusive, referral to a neurologist for additional testing (e.g., electrodiagnostic studies, specific antibody assays, nerve biopsy) should be considered. Treatment of peripheral neuropathy focuses on managing the underlying etiology. Several classes of medications, including gabapentinoids and antidepressants, can help alleviate neuropathic pain.

Entities:  

Mesh:

Year:  2020        PMID: 33320513

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  6 in total

1.  Newly identified chemotherapy-induced peripheral neuropathy in a childhood cancer survivorship clinic.

Authors:  Rozalyn L Rodwin; Wilhelmenia L Ross; Jaime Rotatori; Katherine Allen; Claudia Auerbach; Lyn M Balsamo; Nina S Kadan-Lottick
Journal:  Pediatr Blood Cancer       Date:  2021-12-31       Impact factor: 3.167

Review 2.  Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review.

Authors:  Ryan S D'Souza; Ross Barman; Amira Joseph; Alaa Abd-Elsayed
Journal:  Curr Pain Headache Rep       Date:  2022-06-18

Review 3.  Neuropathy in Human Immunodeficiency Virus: A Review of the Underlying Pathogenesis and Treatment.

Authors:  Lakshya Motwani; Nailah Asif; Apurva Patel; Deepanjali Vedantam; Devyani S Poman
Journal:  Cureus       Date:  2022-06-13

4.  Correlation Analysis and Intervention Study on Disturbance of Lipid Metabolism and Diabetic Peripheral Neuropathy.

Authors:  Wei Wang; Xue Li; Yanzi Ren
Journal:  Comput Math Methods Med       Date:  2022-02-22       Impact factor: 2.238

5.  Evaluation of altered patterns of tactile sensation in the diagnosis and monitoring of leprosy using the Semmes-Weinstein monofilaments.

Authors:  Marco Andrey Cipriani Frade; Fred Bernardes Filho; Claudia Maria Lincoln Silva; Glauber Voltan; Filipe Rocha Lima; Thania Loyola Cordeiro Abi-Rached; Natália Aparecida de Paula
Journal:  PLoS One       Date:  2022-08-10       Impact factor: 3.752

6.  Tuina for diabetic peripheral neuropathy: A protocol for a systematic review and meta-analysis.

Authors:  Fengyang Wang; Fengjuan Wang; Ting Pan; Zhenzhong Wu; Yufeng Wang; Peng Liu; Ziyang Yu; Rui Shang; Bailin Song
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.